We are live on ! Find out more
CELG.RT

Bristol-Myers Squibb Rights

24 hedge funds and large institutions have $57.9K invested in Bristol-Myers Squibb Rights in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more funds holding

Funds holding: 2024 (+4)

0% more ownership

Funds ownership: 0.02%0.02% (+0%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

14% less capital invested

Capital invested by funds: $67K → $57.9K (-$9.1K)

Holders
24
Holders Change
+4
Holders Change %
+20%
% of All Funds
0.32%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
2
Reduced
2
Closed
Calls
Puts
Net Calls
Net Calls Change

CELG.RT Hedge Fund Activity: Q2 2025 in Review

24 of the 7,598 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Rights (CELG.RT) for Q2 2025, worth a combined $57.9K — down 14% from $67K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CELG.RT positions and 0 closed out — a net gain of 4 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $1.13K. The largest seller was Two Sigma Securities, cutting an estimated $112.

  • 24 institutional investors held Bristol-Myers Squibb Rights (CELG.RT) as of Q2 2025, up from 20 in Q1 2025.
  • Funds reported $57.9K of Bristol-Myers Squibb Rights stock for Q2 2025, down 14% quarter-over-quarter.
  • 4 funds opened new Bristol-Myers Squibb Rights positions in Q2 2025 and 0 closed out, a net change of +4 holders.
  • The largest Bristol-Myers Squibb Rights buyer in Q2 2025 was Susquehanna International Group, an estimated $1.13K added.
  • The largest Bristol-Myers Squibb Rights seller in Q2 2025 was Two Sigma Securities, an estimated $112 sold.

Based on aggregated 13F filings for Q2 2025.